CLDX - Celldex TherapeuticsAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $1.66 | Open | $1.62 |
| Volume | 101.4K | Market Cap | 43.1M |
| Yield | Last Dividend |
| The Daily Biotech Pulse: Mylan Ramps Up ... | 03/20/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) ... | |
| The Daily Biotech Pulse: Pfizer's Eczema... | 03/19/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18)... | |
| The Daily Biotech Pulse: Roche Obtains F... | 03/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) ... | |
| Celldex (CLDX) Down 3.9% Since Last Earn... | 12/12/19 |
| Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Celldex Initiates Phase 1 Study of KIT I... | 11/18/19 |
| Celldex Therapeutics, Inc. (CLDX) announced today that a Phase 1a study of CDX-0159 has initiated in healthy volunteers. CDX-0159 is a humanized monoc... | |
| The Week Ahead In Biotech: Smid-Cap Earn... | 11/03/19 |
| Biotech stocks extended their gains last week amid earnings news flow and the broader market strength. Large-cap pharma stocks saw particular strength... | |
| Will Celldex Therapeutics (CLDX) Report ... | 10/30/19 |
| Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with t... | |
| Celldex Therapeutics to Present at the C... | 09/30/19 |
| HAMPTON, N.J., Sept. 30, 2019 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Execut... | |
| Why Is Celldex (CLDX) Down 2.3% Since La... | 09/06/19 |
| Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Celldex Therapeutics (CLDX) Reports Q2 L... | 08/07/19 |
| Celldex (CLDX) delivered earnings and revenue surprises of 28.21% and -43.25%, respectively, for the quarter ended June 2019. Do the numbers hold clue... | |
| The Daily Biotech Pulse: Jounce Jumps On... | 07/24/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 23) ... | |
| Why Is Celldex (CLDX) Down 29.2% Since L... | 06/06/19 |
| Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| The Daily Biotech Pulse: Takeda Pulls Pl... | 06/06/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 5) A... | |
| Celldex Presents Data From CDX-3379 Stud... | 06/04/19 |
| Celldex (CLDX) presents updated data on CDX-3379 and Erbitux combination regimen, which supports further development in biomarker selected patient pop... | |
| The Daily Biotech Pulse: ASCO Presentati... | 06/04/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 3) A... | |
| Celldex Therapeutics Continues to Stretc... | 05/08/19 |
| The clinical-stage biotech effectively conserved cash in the first quarter, thanks to cost cuts following last year's pipeline setback with experiment... | |
| Celldex Therapeutics (CLDX) Reports Q1 L... | 05/07/19 |
| Celldex (CLDX) delivered earnings and revenue surprises of 0.88% and 13.10%, respectively, for the quarter ended March 2019. Do the numbers hold clues... | |
| Celldex misses by $0.26, beats on revenu... | 05/07/19 |
| No summary available. | |
| Celldex Therapeutics (CLDX) May Report N... | 05/02/19 |
| Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with t... | |
| Catalyst in Focus: Celldex Therapeutics ... | 04/23/19 |
| CD40 space has received more attention after private company Apexigen's promising results in pancreatic cancer (combined with Opdivo and chemo). | |
| Microcaps dominate midday movers | 04/08/19 |
| No summary available. | |
| Celldex (CLDX) Down 5.7% Since Last Earn... | 04/06/19 |
| Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| WBA, EVOK and UGI among premarket losers | 04/02/19 |
| No summary available. | |
| Celldex Presents Positive Interim Result... | 04/02/19 |
| --CDX-1140 has achieved good systemic exposure without reaching a maximum tolerated dose to date-- --Addition of dendritic cell growth factor CDX-301 ... | |
| Is Celldex Therapeutics (CLDX) Stock Out... | 03/20/19 |
| Is (CLDX) Outperforming Other Medical Stocks This Year? | |
| Celldex Therapeutics, Inc. (CLDX) CEO An... | 03/07/19 |
| No summary available. | |
| Celldex beats by $0.39, beats on revenue | 03/07/19 |
| No summary available. | |
| Mallinckrodt and Aerie Pharmaceuticals a... | 02/26/19 |
| No summary available. | |
| NuVasive and OHR Pharmaceutical among he... | 02/11/19 |
| No summary available. | |
| Post-reverse split trading in Celldex co... | 02/11/19 |
| No summary available. | |
| Buy rating | 03/27/20 |
| and lowers Price Target from $19.00 to $16.00 | |
| Strong Buy rating | 02/21/20 |
| Cantor Fitzgerald initiates coverage with Overweight rating and announces Price Target of $8.00 | |
| Date | 2020-03-26 (AMC) | Est. (EPS/Rev.) | ($0.90)/ 810K |
| Actual (EPS/Rev.) | $-0.64/ $887.00 K | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Arbitrage Trade Analytics | Royce Wells | 71.00 % | Subscribe |
| Swing Trading Cheap Stocks <~ $10 | Michael S. DeVries | 64.00 % | Follow |
| LavaPit | Steve Pitkin | 57.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
